The Influence of TP53 Expression on K562 Cell Lipid Metabolism and Differentiation

The Influence of TP53 Expression on K562 Cell Lipid Metabolism and Differentiation

Saved in:

Bibliographic Details
Main Authors:	McKale Montgomery, Cameron J Cardona, Madelyne Young
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Current Developments in Nutrition
Online Access:	http://www.sciencedirect.com/science/article/pii/S2475299125027684
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Investigation of Calnexn Protein Expression in Imatinib Sensitive and Resistant K562 Cells
by: Arzu Z. Karabay
Published: (2018-04-01)

Analyzing inhibition of BCL11A gene expression in K562 cells by RNAi
by: Vikas Urkude
Published: (2014-08-01)

TP63 as a modulator of ferroptosis in TP53 mutations glioblastoma
by: Haiping Cai, et al.
Published: (2025-08-01)

TP53 drives invasion through expression of its Δ133p53β variant
by: Gilles Gadea, et al.
Published: (2016-09-01)

Correction: TP53 drives invasion through expression of its Δ133p53β variant
by: Gilles Gadea, et al.
Published: (2025-05-01)

A systematic analysis of the network of lncRNAs and mRNAs regulated by TP53 and TP53 mutants with hotspot mutations
by: Hong Chen, et al.
Published: (2025-07-01)

Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma
by: Xiaoyan Tang, et al.
Published: (2024-12-01)

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block
by: Jiexian Ma, et al.
Published: (2025-02-01)

<i>TP53</i> Mutations in Chagasic Megaesophagus
by: Aparecida Perpetuo Fedossi Silveira, et al.
Published: (2025-03-01)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2023-06-01)

Defects in mitophagy promote redox‐driven metabolic syndrome in the absence of TP53INP1
by: Marion Seillier, et al.
Published: (2015-03-01)

In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer
by: Lucie Vanikova, et al.
Published: (2025-08-01)

Investigating The Impact Of Homoharringtonine On K562 Cell Viability And ER Stress Pathways
by: Wang Meishi, et al.
Published: (2025-01-01)

Role of Phosphoramidate Antisense in Specific Inhibition of K562 Leukemic Cell Line
Published: (2006-09-01)

The induction effect of hydroxyurea and metformin on fetal globin in the K562 cell line
by: Mohammad Eini, et al.
Published: (2025-04-01)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
by: Junjie Li, et al.
Published: (2021-01-01)

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC
by: Yun Sun Lee, et al.
Published: (2017-06-01)

FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer
by: Yan Li, et al.
Published: (2025-07-01)

TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy
by: Yun Sun Lee, et al.
Published: (2018-08-01)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
by: Emma Haapaniemi, et al.
Published: (2019-08-01)

Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer
by: Regina Mirgayazova, et al.
Published: (2024-12-01)

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms
by: Qiang Ma, et al.
Published: (2024-12-01)

Detecting PI3K and TP53 Pathway Disruptions in Early‐Onset Colorectal Cancer Among Hispanic/Latino Patients
by: Cecilia Monge, et al.
Published: (2025-04-01)

The FBP1‐TP53‐NRF2 metabolic switch in metabolic dysfunction‐associated steatohepatitis‐hepatocellular carcinoma progression and senescence reversal
by: Yahui Zhu, et al.
Published: (2025-04-01)

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells
by: Alphy Rose James, et al.
Published: (2017-02-01)

Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion
by: Robert K. McCall, et al.
Published: (2020-01-01)

A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group
by: Subhalakshmi Sengupta, et al.
Published: (2012-01-01)

Analysis of KRT1, KRT10, KRT19, TP53 and MMP9 expression in pediatric and adult cholesteatoma.
by: Enikő Palkó, et al.
Published: (2018-01-01)

The Critical Role of TP53 in Developing Leukaemia in Human and Dogs, Review Article
by: ِAoula Al-Zebeeby, et al.
Published: (2025-06-01)

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
by: Ethan J. Harris, et al.
Published: (2025-08-01)

Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy
by: Menglei Zhang, et al.
Published: (2025-05-01)

Insights into an uncommon case: axillary extramammary Paget’s disease and TP53 mutation
by: Julia Zawistowska, et al.
Published: (2025-01-01)

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis
by: Vishesh Khanna, et al.
Published: (2025-02-01)

Two Functional TP53 Genetic Variants and Predisposition to Keloid Scarring in Caucasians
by: Andrzej Dmytrzak, et al.
Published: (2019-01-01)

Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications
by: Yang Si, et al.
Published: (2024-12-01)

Mosaic TP53 Mutation on Tumour Development in Pigs: A Case Study
by: Chommanart Thongkittidilok, et al.
Published: (2023-01-01)

Characteristics predicting reduced penetrance variants in the high-risk cancer predisposition gene TP53
by: Cristina Fortuno, et al.
Published: (2025-10-01)

Deciphering the Controversial Role of TP53 Inducible Glycolysis and Apoptosis Regulator (TIGAR) in Cancer Metabolism as a Potential Therapeutic Strategy
by: Fatima I. AlMaazmi, et al.
Published: (2025-04-01)

Pathogenic TP53 mutations influence chemotherapy response and survival rate of HPV-negative oral carcinomas
by: Jović Saša, et al.
Published: (2022-01-01)

TP53 Gene Mutations in Tumor Cells of Patients with Aggressive B-Cell Lymphomas
by: AE Misyurina, et al.
Published: (2019-05-01)